Nouscom
Develops tumor specific oncolytic viruses and patient specific cancer vaccines
Basel, Switzerlandwww.nouscom.com ↗
Total raised
€54M
€54,000,000
Funding rounds
2
Investors
4
distinct backers
Active since
2016-04
latest 2017-11
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood20
base rate 48% for Series B
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood16
base rate 12% (2+ rounds)
- ▲ €30M+ raised
- ▲ 10y since founding
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2017-11-07 | Series B | €42M | 5AM Ventures,Abingworth,LSP,Versant Ventures | View deal → |
| 2016-05-01 | Series A | €12M | LSP,Versant Ventures | View deal → |
Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Climeworks€920MSwitzerland · Cleantech
- Energy Vault€896MSwitzerland · Energy